Partnership Valuation in Pharma

Valuation: The complete toolbox for getting the most out of partnerships!

Medical & Health Care, Pharmaceuticals/Drug Discovery

Partnership Valuation in Pharma 1-2 Dec 2014 Mövenpick Hotel Berlin, Berlin, Germany
Submit new post
Thank you for posting.
Share it:

• Deepen your understanding of the complex aspects in valuation of products, companies and technology platforms
• Listen to best practice examples from pharmaceutical and biotech companies, their strategies and tools to master challenges like pricing and reimbursement
• Hear about the different valuation models of early stage products versus late stage products

Companies and institutes invited to speak:
• AstraZeneca AB
• Merck and Co.
• Bayer Pharma AG
• Novartis AG
• Hoffmann-La Roche Ltd.
• Medivir AB
• Avance
• Gilead Sciences, Inc.
• Boehringer Ingelheim GmbH
• Sanofi S.A.
• Bayer Schering Pharma AG
• Polyphor Ltd.
• Grünenthal GmbH
• Novo Nordisk A/S
• Merck Serono
• Amgen, Inc.
• Pfizer, Inc.
• Astellas Pharma, Inc.
• MorphoSys AG
• UCB Pharma Ltd.

Bronze Package 2 day conference: €2,549,- + VAT

Speakers: Dr. Kay Brickmann - Business Development Director Scientific Partnering and Alliances - AstraZeneca AB - Sweden, Morten Faester - Director Business Development - Medivir AB - Sweden, Ralph Villiger - Managing Director - Avance - Switzerland